Dover, DE, Oct. 25, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics, today announced that a new poster is live at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The work, conducted with investigators from the Italian Group for Mesothelioma (G.I.Me) and collaborators, provides the first evidence that selective adenosine A2B receptor inh ...